Biochemical evaluation of bone turnover in cancer patients with bone metastases: Relationship with radiograph appearances and disease extension

British Journal of Cancer

Volumn 73, Issue 12, 1996, Pages 1581-1587

  Berruti, A ^a   Piovesan, A ^a   Torta, M ^a   Raucci, C A ^a   Gorzegno, G ^a   Paccotti, P ^a   Dogliotti, L ^a,b   Angeli, A ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Bone hunger syndrome; Bone metastases; Bone turnover

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; COLLAGEN TYPE 1; CREATININE; OSTEOCALCIN; PARATHYROID HORMONE; PROCOLLAGEN;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; BLOOD LEVEL; BONE METASTASIS; BONE SCINTISCANNING; BONE TURNOVER; CALCIUM URINE LEVEL; CANCER PATIENT; COLLAGEN METABOLISM; CONTROLLED STUDY; CREATININE URINE LEVEL; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; X RAY FILM;

EID: 0030036375     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.298     Document Type: Article

References (27)

1. AZRIA M. (1989). The value of biomarkers in detecting alterations in bone metabolism. Caleif. Tissue Int., 45, 7-11.
2. CAMPBELL FC, BLAMEY RW, WOOLFSON AMJ, ELSTON CW AND HOSKING DJ. (1983). Calcium excretion (CaE) in metastatic breast cancer. Br. J. Surg., 70, 202-204.
3. CARTER RL. (1985). Patterns and mechanisms of bone metastases. J. R. Soc. Med., 78 (suppl. 9), 2-6.
4. CLARKE NW, MCCLURE J AND GEORGE NJR. (1991). Morphometric evidence for bone resorption and replacement in prostate cancer. Br. J. Ural., 68, 74-80.
5. COLEMAN RE. (1994). Evaluation of bone disease in breast cancer. The Breast, 3, 73-78.
6. COLEMAN RE, WHITAKER KD, MOSS DW, MASHITER G, FOGELMAN I AND RUBENS RD. (1988). Biochemical monitoring predicts response in bone metastases to treatment. Br. J. Cancer, 58, 621-625.
7. DELMAS PD. (1993). Biochemical markers of bone turnover. J. Bone Miner. Res., 8 (suppl. 2), S549-S555.
8. HANSON DA, WEIS MAE, BOLLEN A-M, MASLAN SL, SINGER FR AND EYRE DR. (1990). A specific immunoassay for monitoring human bone resorption: quantitation of type collagen cross-linked N-telopeptide in urine. J. Bone Miner. Res., 7, 1251-1258.
9. HOSKING DJ. (1990). Advances in the management of Paget's disease in bone. Drugs, 40, 829-840.
10. JACOBS SC. (1983). Spread of prostatic cancer to bone. Urology, 21, 337-344.
11. MEIKKO J. NIEMI S, RISTELI L AND RISTELI J. (1990). Radio-immunoassay of the carboxyterminal propeptide of human type 1 procollagen. Clin. Chem., 36, 1,328-1332.
12. MORO L, GAZZARINI C, CRIVELLARI D, GALLIGIONI E, TALAMINI R AND DE BERNARD B. (1993). Biochemical markers for detecting bone metastases in patients with breast cancer, Clin. Chem., 39, 131-134.
13. MUNDY GR. (1990). Incidence and pathophysiology of hypercalcemia. Calcif. Tissue Int., 46 (suppl.), 3-10.
14. MUNDY GR. (1991). Mechanisms of osteolytic hone destruction. Bone, 12 (suppl. 1), S1-S6.
15. NORUSIS MJ. (1990). SPSS Inc 444 N. Michigan Avenue: Chicago, II.
16. PATERSON AHG. (1987). Bone metastases in breast cancer, prostate cancer and myeloma. Bone, 8 (suppl. 1) 17-22.
17. PATERSON CR, ROBINS SP, HOROBIN JM, PREECE PE AND CUSCHIERI A. (1991). Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. Br. J. Cancer. 64, 884-886.
18. PEACOCK M ROBERTSON WG AND NORDIN. (1969). Relation between serum and urinary calcium with particular reference to parathyroid hormone. Lancet 1, 384-386.
19. PECHERSTRORFER M, ZIMMER-ROTH I. SHILLING T, WOITGE HW, SCHMIDT H, BAUMGARTNER G, THIÉBAUD D, LUDWIG H AND SEIBEL JM. (1995). The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase and urinary calcium excretion in neoplastic bone disease. J Clin. Endocrinol. Metab., 80, 97-103.
20. RIANCHO JA, ARJONA R, VALLE R, SANZ J AND GONZALKSMACTAS J. (1989). The clinical spectrum of hypocalcemia associated with bone métastases. J. Intern. Med., 226, 449-452.
21. RICO H, USON A, HERNANDEZ ER, PRADOS P, PARAMO P AND CABRANES JA. (1990). Hyperparathyroidism in metastases of prostatic carcinoma: a biochemical, hormonal and histomorphometric study. Eur. Urol., 17, 35-39.
22. RISTELI J, ELOMAA I, NIEMI S, NOVAMO A AND RISTELI L. (1993). Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin. Chem., 39, 635-640.
23. STEWARD AF AND BROADUS AE. (1990). Clinical review 16: parathyroid hormone-related proteins: coming of age in the 1990s. J Clin. Endocrinol. Metab., 71, 1410-1414.
24. STOLL BA. (1983). Natural history, prognosis and staging of bone metastases. In Bone Metastases Monitoring and Treatment, Stoll BA, Parbho S. (eds), pp. 1-20. Raven Press: New York.
25. TERZOLO M, PIOVESAN A, OSELLA G, PIA A, REIMONDO G, POZZI C, RAUCCI C, TORTA M, PACCOTTI P AND ANGELI A. (1993). Serum levels of bone GLA protein (osteocalcin, BGP) and carboxyterminal propeptide of type I procollagen (PICP) in acromegaly: effects of long term octreotide treatment. Calcif. Tissue Int., 52, 188-191.
26. UEBELHART D, GINEYTS E, CHAPUY MC AND DELMAS PD. (1990). Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone & Mineral, 8, 87-96.
27. URWIN GH, PERCIVAL RC, HARRIS S, BENETON MNC, WILLIAMS JL AND KANIS JA. (1985). Generalised increase in bone resorption in carcinoma of the prostate. Br. J. Urol., 57, 721-723.